HELX Franklin Genomic Advancements ETF
Quote as of Oct 09, 2026 19:59 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 41.85 | Day Range | 42.64 – 42.91 |
| 52-Week Range | 31.24 – 45.58 | Volume | 131.01K |
| Avg Volume | 3.70K | AUM | $29.3M (Oct 10, 2026) |
| Expense Ratio | 0.50% | Yield (TTM) | 0.34% |
| NAV | 41.83 | Premium/Discount | +1.94% indicative |
| Inception | Feb 25, 2020 | Holdings | 63 |
| Issuer | Franklin Templeton | Exchange | CBOE |
| Category | Healthcare | Index Tracked | Not stated in source data |
| CUSIP | 35473P520 | ISIN | US35473P5200 |
| Management | Not stated in source data | ||
About this ETF
This fund aims to generate substantial capital growth by strategically investing in a diverse array of equity securities. Its portfolio includes companies based within the United States as well as those operating in international markets, encompassing both established and emerging economies. The core investment thesis of the fund centers on companies engaged in genomic advancements. Specifically, it seeks out firms that the investment manager believes are fundamentally dedicated to, or are poised to significantly benefit from, efforts to prolong and enhance the overall quality of life for both humans and animals. This is accomplished by integrating cutting-edge technological and scientific innovations, improvements, and breakthroughs in the field of genomics directly into their business models and operations.
Description from the fund data provider · profile as of Oct 10, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +2.62% | +6.12% | +30.40% | +17.43% | +29.57% | +14.41% | -2.87% | — | +9.11% |
| Total return | +2.62% | +6.12% | +30.40% | +17.43% | +30.08% | +14.56% | -2.75% | — | +9.23% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Oct 09, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.50% | Annual cost of a $10,000 investment | $50.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Oct 10, 2026 · portfolio reporting date from the data provider; holdings are not live positions. 71 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | NATERA INC | NTRA | 10.29% | 7.68K | $3.1M |
| 2 | GUARDANT HEALTH INC | GH | 9.48% | 16.93K | $2.8M |
| 3 | KRYSTAL BIOTECH INC | KRYS | 5.28% | 4.76K | $1.6M |
| 4 | ADAPTIVE BIOTECHNOLOGIES | ADPT | 4.60% | 51.96K | $1.4M |
| 5 | TWIST BIOSCIENCE CORP | TWST | 4.53% | 8.46K | $1.4M |
| 6 | LIGAND PHARMACEUTICALS | LGND | 4.49% | 4.45K | $1.3M |
| 7 | BRIDGEBIO PHARMA INC | BBIO | 2.87% | 13.13K | $858.0K |
| 8 | MEDPACE HOLDINGS INC | MEDP | 2.71% | 1.32K | $808.5K |
| 9 | VERTEX PHARMACEUTICALS IN | VRTX | 2.64% | 1.54K | $788.1K |
| 10 | UNITED THERAPEUTICS CORP | UTHR | 2.63% | 1.43K | $785.3K |
| 11 | TRAVERE THERAPEUTICS INC | TVTX | 2.47% | 14.14K | $737.2K |
| 12 | ELI LILLY & CO | LLY | 2.37% | 601 | $708.7K |
| 13 | VYLOR INC | VYLR | 2.24% | 9.15K | $669.1K |
| 14 | GRAIL INC | GRAL | 2.10% | 4.46K | $626.4K |
| 15 | REGENERON PHARMACEUTICALS | REGN | 2.01% | 805 | $601.0K |
| 16 | TEMPUS AI INC-CL A | TEM | 1.94% | 8.19K | $580.9K |
| 17 | REPLIGEN CORP | RGEN | 1.94% | 3.33K | $579.4K |
| 18 | CAREDX INC | CDNA | 1.70% | 8.00K | $509.4K |
| 19 | CHARLES RIVER LABORATORIE | CRL | 1.57% | 1.56K | $469.6K |
| 20 | NEUROCRINE BIOSCIENCES IN | NBIX | 1.46% | 3.06K | $435.6K |
| 21 | ARGENX SE | ARGX.BR | 1.35% | 494 | $402.9K |
| 22 | JAZZ PHARMACEUTICALS PLC | JAZZ | 1.29% | 1.77K | $386.4K |
| 23 | 10X GENOMICS INC-CLASS A | TXG | 1.26% | 4.68K | $377.7K |
| 24 | BIONTECH SE-ADR | BNTX | 1.19% | 3.67K | $355.5K |
| 25 | PTC THERAPEUTICS INC | PTCT | 1.08% | 5.01K | $324.1K |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.34% | Paid (last 12 months) | $0.1433 |
| Frequency | Irregular | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | Dec 30, 2025 | Last payment | $0.1433 (Jan 08, 2026) |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Dec 30, 2025 | Dec 30, 2025 | Jan 08, 2026 | $0.1433 |
| Dec 30, 2021 | Dec 31, 2021 | Jan 07, 2022 | $0.0040 |
| Dec 13, 2021 | Dec 14, 2021 | Dec 21, 2021 | $0.1140 |
| Dec 14, 2020 | Dec 15, 2020 | Dec 23, 2020 | $0.0520 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 23.94% / 22.24% | Sharpe 1Y / 3Y | 1.38 / 0.61 |
| Max drawdown 1Y / 3Y | -18.00% / -29.48% | Sortino 1Y | 2.13 |
| Beta vs S&P 500 (3Y) | 0.936 | Correlation vs S&P 500 (1Y) | 0.483 |
| Downside deviation 1Y | 15.45% | Risk-free rate used | 4.05% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Oct 11, 2026. Formulas →
Liquidity
| Volume today | 131.01K | Average volume | 3.70K |
| AUM | $29.3M | Premium/Discount | +1.94% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | -$400.0K | -1.35% | $29.7M → $29.3M |
| 1 Month | -$3.1M | -10.09% | $31.2M → $29.3M |
| 1 Week | -$2.6M | -7.86% | $32.7M → $29.3M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for HELX
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.